Aug 30, 2021 4:01pm EDT Sonnet Announces Successful Completion of the Discovery Phase for Its Next Preclinical Pipeline Candidate (SON-1410)
Aug 19, 2021 9:35pm EDT Sonnet BioTherapeutics Announces Pricing of $30 Million Underwritten Public Offering
Aug 16, 2021 6:30am EDT Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update
Jun 08, 2021 4:30pm EDT Sonnet BioTherapeutics Announces Issuance of U.S. Patent for Platform Technology
May 17, 2021 7:00am EDT Sonnet BioTherapeutics Provides Fiscal Year 2021 Second Quarter Business and Earnings Update
May 10, 2021 6:30am EDT Sonnet BioTherapeutics Completes Successful GLP Repeat Dose Toxicology Study of IL12-FHAB (SON-1010) in Non-Human Primates (NHP)
May 03, 2021 6:00am EDT Sonnet BioTherapeutics Completes Licensing Agreement with New Life Therapeutics
Mar 22, 2021 7:00am EDT Sonnet BioTherapeutics Appoints Richard Kenney as Chief Medical Officer and Manuel Dafonseca as Head of Clinical Operations
